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to study synaptic transmission. We show that exposure to 
MMF switches the molecular and functional phenotype of 
activated microglia from classically activated, pro-inflam-
matory type to alternatively activated, neuroprotective one, 
through activation of the hydroxycarboxylic acid receptor 
2 (HCAR2). We validate a downstream pathway medi-
ated through the AMPK–Sirt1 axis resulting in deacetyla-
tion, and thereby inhibition, of NF-κB and, consequently, 
of secretion of pro-inflammatory molecules. We demon-
strate through ex vivo monitoring of spontaneous gluta-
mate-mediated excitatory post-synaptic currents of single 
neurons in corticostriatal slices from EAE mice that the 
neuroprotective effect of DMF was exerted on neurons at 
pre-synaptic terminals by modulating glutamate release. By 
exposing control slices to untreated and MMF-treated acti-
vated microglia, we confirm the modulating effect of MMF 
on microglia function and, thereby, its indirect neuroprotec-
tive effect at post-synaptic level. These findings, whereby 
DMF-induced activation of a new HCAR2-dependent path-
way on microglia leads to the modulation of neuroinflam-
mation and restores synaptic alterations occurring in EAE, 
represent a possible novel mechanism of action for DMF 
in MS.
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Introduction
Dimethyl fumarate (DMF) was recently approved as a first-
line oral therapy for multiple sclerosis (MS), an inflam-
matory autoimmune disease of the CNS characterized by 
Abstract Dimethyl fumarate (DMF), recently approved 
as an oral immunomodulatory treatment for relapsing-
remitting multiple sclerosis (MS), metabolizes to mono-
methyl fumarate (MMF) which crosses the blood–brain 
barrier and has demonstrated neuroprotective effects in 
experimental studies. We postulated that MMF exerts 
neuroprotective effects through modulation of microglia 
activation, a critical component of the neuroinflammatory 
cascade that occurs in neurodegenerative diseases such as 
MS. To ascertain our hypothesis and define the mechanistic 
pathways involved in the modulating effect of fumarates, 
we used real-time PCR and biochemical assays to assess 
changes in the molecular and functional phenotype of 
microglia, quantitative Western blotting to monitor activa-
tion of postulated pathway components, and ex vivo whole-
cell patch clamp recording of excitatory post-synaptic cur-
rents in corticostriatal slices from mice with experimental 
autoimmune encephalomyelitis (EAE), a model for MS, 
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demyelination and axonal loss, following phase III clinical 
trials which showed that DMF successfully reduced relapse 
rate and the number of new lesions on MRI [13, 18], and 
increased time to progression of disability in relapsing-
remitting MS patients [18]. The mode of action of DMF is 
only partially understood, but in vitro and in vivo studies 
suggest that DMF and its active metabolite, monomethyl 
fumarate (MMF), modulate immune cells. In particular, 
DMF was shown to switch T cells from a Th1- to a Th2-
type profile in vitro and in vivo [27], an effect possibly 
related to the induction of type II dendritic cells that pro-
mote Th2-type T cells [16], and/or inhibition of dendritic 
cell maturation, thereby affecting Th1 and Th17 cell dif-
ferentiation [34]. Studies in experimental autoimmune 
encephalomyelitis (EAE), an experimental model of MS, 
have demonstrated that oral administration of DMF in 
EAE mice ameliorated the clinical course of the disease, 
both when applied as a preventive (prior to disease onset) 
or a therapeutic (at disease chronic phase) treatment [28, 
45]. Upon oral administration, DMF is rapidly metabo-
lized to MMF, which crosses the blood–brain barrier and 
achieves detectable levels in the CNS [19, 28], support-
ing the potential for a direct effect on CNS resident cells. 
Several studies have postulated that fumarates, as thiol-
reactive electrophilic agents, could act through the nuclear 
factor (erythroid-derived 2)-like 2 (Nrf2) pathway, which 
mediates induction of phase II genes by thiol-reactive elec-
trophiles, thereby playing a major role in cell and tissue 
defense against oxidative stress [54]. In vitro analysis of 
the effect of MMF on neurons and astrocytes exposed to 
oxidative stress showed that MMF induced the activation of 
the Nrf2 oxidative response pathway in these cells [43], an 
effect validated by ex vivo immunohistochemical analysis 
of spinal cord tissue from DMF-treated EAE mice show-
ing increased Nrf2 protein expression in NeuN-positive 
cells [28]. However, Nrf2-independent mechanisms might 
also be involved in the immunomodulatory effect of DMF 
[46] and a recent study showed that the hydroxycarboxylic 
acid receptor 2 (HCAR2), a G protein-coupled membrane 
receptor, was required for the therapeutic effects of DMF in 
EAE, possibly through inhibition of neutrophil infiltration 
[10]. DMF has been shown to also affect astrocytes and 
microglia, inhibiting their production of neuroinflamma-
tory mediators [55]. In chronic inflammatory diseases such 
as MS, microglia become activated and release pro-inflam-
matory cytokines and stress-associated molecules lead-
ing to neurodegeneration and alteration of synaptic trans-
mission [9]. However, modulation of microglia activation 
towards an alternatively activated phenotype, favoring neu-
roprotection, can modify the outcome of some experimen-
tal models of neurological diseases [17]. Here, we show 
that in vitro application of MMF to microglia switches the 
phenotype of activated microglia from pro-inflammatory 
to anti-inflammatory, with downregulation of pro-inflam-
matory markers and upregulation of neuroprotective ones. 
We demonstrate that microglia express HCAR2 and that 
MMF binding to HCAR2 triggers a pathway driven by the 
AMPK/Sirt axis resulting in inhibition of NF-κB and of 
subsequent pro-inflammatory cytokine production. Finally, 
we validate that DMF administration to mice with EAE 
results in upregulation of microglia markers associated 
with neuroprotection and mitigates deleterious alterations 
in synaptic transmission.
Materials and methods
Microglia culture and treatments
The murine microglial cell line N9 developed by Prof. P. 
Ricciardi-Castagnoli and kindly provided by Prof. E. Zoc-
chi, Genoa, Italy, was obtained by immortalization of murine 
microglial cells from embryonic day 13 with the 3RV retrovi-
rus carrying an activated vmyc oncogene [39]. N9 cells were 
grown in Iscove’s Modified Dulbecco’s Medium (IMDM, 
Lonza) supplemented with 5 % fetal bovine serum, 1 % 
penicillin and streptomycin, and 50 nM β-mercaptoethanol, 
and cultured in a humidified 5 % CO2 atmosphere at 37 °C. 
N9 cells seeded in 6-well plates (8 × 105 cells/well) in 
3 ml IMDM were activated with 1 μg/ml LPS (Sigma-
Aldrich) for various times, as indicated in the text and/or 
figure legends and treated concomitantly with MMF (1 μM 
in 0.001 % dimethyl sulfoxide final concentration, except 
where indicated). Where relevant, N9 cells were incubated 
with anti-HCAR2 antibody (anti-mouse HCAR2, Novus 
Biologicals, NBP1-00875; 1 μg/ml) for 1 h prior to activa-
tion with LPS in the presence or absence of MMF. Treat-
ments with EX527 and resveratrol (Resv; Sigma-Aldrich) 
are detailed in the legend to the relevant figure.
Cytotoxicity assay
N9 cells were seeded in 96-well plates (5 × 104 in 200 μl 
of IMDM) and treated, or not, with different concentrations 
of MMF (1 μM, 10 μM, 100 μM) for 24 h. The medium 
was then replaced by serum-free IMDM containing 10 % 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium Bromide, Sigma-Aldrich) and cell viability was meas-
ured by spectrophotometric absorbance at 570 nm. Per-
centage viability was calculated as optical density (OD) of 
treated sample/OD of untreated sample × 100.
RNA isolation and real‑time PCR
Total RNA was isolated from N9 cells and EAE brains 
using Trizol reagent (Life Technologies) according to the 
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manufacturer’s instructions. cDNA was synthetized from 
1 μg RNA using the Transcriptor First Strand cDNA Syn-
thesis Kit (Roche). Real-time PCR was performed using a 
LightCycler 480 (Roche) in duplicates with a final reac-
tion volume of 20 μl containing 50 ng cDNA, 1 μl of 
each primer pair (20 μM), and 10 μl of LightCycler 480 
SYBR Green I Master Mix (Roche). Amplification of glyc-
eraldehyde 3-phosphate dehydrogenase (Gapdh) was used 
to normalize the expression data. The primer pairs for the 
indicated genes were synthetized by Tib Molbiol according 
to the following sequences: Tnf, forward primer: 5′-TCTT 
CTCATTCCTGCTTGTGG-3′, reverse primer: 5′-GGTCT 
GGGCCATAGAACTGA-3′; Il1b, forward primer: 5′-AG 
TTGACGGACCCCAAAAG-3′, reverse primer: 5′-TTTGA 
AGCTGGATGCTCTCAT-3′; Spi1, forward primer: 5′-GG 
GATCTGACCAACCTGGA-3′, reverse primer: 5′-AACCA 
AGTCATCCGATGGAG-3′; Nos2, forward primer: 5′-TGA 
ACTTGAGCGAGGAGCA-3′, reverse primer: 5′-TTCATG 
ATAACGTTTCTGGCTCT-3′; Hmox1, forward primer: 
5′-GTCAAGCACAGGGTGACAGA-3′, reverse primer: 
5′-ATCCCTGCAGCTCCTCAAA-3′; Cx3cr1, forward 
primer: 5′-AAGTTCCCTTCCCATCTGCT-3′, reverse 
primer: 5′-CAAAATTCTCTAGATCCAGTTCAGG-3′, 
Cd200r, forward primer: 5′-AAATGCAAATTGCCAAA 
ATTAGA-3′, reverse primer: 5′-GTATAGTAGCATAAG 
GCTGCATTT-3′; Nr4a2, forward primer: 5′-TCAGAGCC-
CACGTCGATT-3′, reverse primer: 5′-TAGTCAGGGTTT-
GCCTGGAA-3′; Igf1, forward primer: 5′-AGCAGCCTTC-
CAACTCAATTAT-3′, reverse primer: 5′-GAAGACGACA 
TGATGTGTATCTTTATC-3′, Arg1, forward primer: 5′-GA 
ATCTGCATGGGCAACC-3′, reverse primer: 5′-GAATCT 
GGTACATCTGGGAAC-3′, Retnla1, forward primer: 5′-CC 
CTCCACTGTAACGAAGACTC-3′, reverse primer: 5′-CA 
CACCCAGTAGCAGTCATCC-3′; Trem2, forward primer: 
5′-TGGGACCTCTCCACCAGTT-3′, reverse primer: 5′-GT 
GGTGTTGAGGGCTTGG-3′; Lgals3, forward primer 
5′-AAGGAGAACAGGGCAAAGG-3′, reverse primer: 5′- 
TGGACTTGCAGGGCTTCT-3′; Mrc1, forward primer: 
5′-CCACAGCATTGAGGAGTTTG-3′, reverse primer: 
5′-ACAGCTCATCATTTGGCTCA-3′; Gapdh: forward 
primer: 5′-AATCTCCACTTTGCCACTGC-3′, reverse 
primer: 5′-ATGGTGAAGGTCGGTGTGA-3′.
Phagocytosis assay
N9 cells (8 × 105) plated on 35-mm glass-bottom cell cul-
ture dishes were activated or not with LPS in the presence 
or absence of MMF. After 24 h, cells were incubated with 
10 μl of Fluoresbrite microspheres (Polysciences Inc.) for 
30 min at 37 °C. The phagocytic activity was blocked by 
addition of ice-cold PBS and the cells were washed twice 
with ice-cold PBS. Several hundred N9 cells were analyzed 
by confocal microscopy (TCS SP5, LEICA Microsystems) 
and the extent of phagocytosis was quantified as follows: 
for every cell analyzed, the area of the maximal confo-
cal section was measured, the fluorescence emitted by the 
beads was binarized in the same section and the total area 
of the fluorescent surface was measured; the ratio between 
the fluorescent area and the cell section area was calculated 
and phagocytosis was quantified as the area occupied by 
the microspheres.
Fluorimetric determination of intracellular Ca2+ 
concentration ([Ca2+]i)
N9 cells (5 × 105) were plated on 20-mm-diameter cov-
erslips and activated, or not, with LPS in the presence or 
absence of MMF for 24 h. Cells were then incubated with 
the fluorescent calcium indicator Fura-2-acetoxymethyl 
ester (Fura 2 AM) for 45 min at 37 °C, and [Ca2+]i was 
measured as fluorescent intensity on an inverted micro-
scope (Zeiss IM35, Zeiss) as described elsewhere [63].
Immunochemistry and confocal microscopy
N9 cells were seeded on 20-mm glass coverslip (5 × 105 
cells per coverslip) overnight. The next day, cells were 
fixed with 4 % paraformaldehyde (PFA) for 10 min at room 
temperature and permeabilized with 0.25 % Triton X 100 
for 10 min. After blocking in 1 % bovine serum albumin 
(BSA) for 15 min at room temperature, cells were stained 
for 1 h in humid chamber with primary antibodies: rab-
bit anti-HCAR2 (1:200, Novus Biologicals) and rat anti-
CD11b (1:100, Abnova, ab8879) in 1 % BSA. Cells were 
then incubated with Alexa 488-labeled anti-rabbit and 
Alexa 594-labeled anti-rat secondary antibodies (both used 
at 1:500, Life Technologies, A-11034 and A-11007) at 
room temperature for 30 min and the nuclei were identi-
fied with 4,6-diamidino-2-phenylindole (DAPI). Images 
were analyzed by confocal microscopy (TCS SP5, LEICA 
Microsystems GmbH).
Western blotting
N9 cells were lysed in RIPA buffer containing protease 
inhibitor cocktail (Roche) and phosphatase inhibitor cock-
tail (Sigma-Aldrich). Protein samples (30 μg) were elec-
trophoresed on a 4–12 % gradient polyacrylamide pre-cast 
gel (Life Technologies), using Bolt® Mini Gel Tank (Life 
Technologies) and transferred to nitrocellulose mem-
brane (BioRad) using XCell II™ Blot Module (Life Tech-
nologies). Membranes blocked with 5 % non-fat milk in 
PBS/0.1 % Tween 20 were incubated with primary anti-
bodies overnight, washed and incubated with horseradish 
peroxidase-conjugated anti-rabbit IgG (1:4000, Merck-
Millipore, AP307P) for 1 h, and visualized using ECL 
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Plus (Thermo Fisher Scientific). Quantification of relative 
protein amounts was performed by densitometric analy-
sis using ImageJ software (NIH), normalized to a loading 
control protein, growth factor receptor-bound protein 2 
(GRB2). Primary rabbit antibodies used were: anti-phos-
pho-5′ adenosine monophosphate-activated protein kinase 
(AMPK) Thr172 (1:1000, Cell Signaling, 2535), anti-
AMPK (1:3000, Cell Signaling, 2603), anti-acetyl-nuclear 
factor kappa-light-chain-enhancer of activated B cells (NF-
κB) Lys310 (1:1000, Cell Signaling, 3045), anti-NF-κB 
(1:3000, Cell Signaling, 4764), and anti-GRB2 (1:2000, 
Abcam, ab32111) antibodies.
Nicotinamide adenine dinucleotide (NAD)+ 
quantification
N9 cells seeded overnight in 96-well plates (5 × 104 cells/
well) were incubated, or not, with anti-HCAR2 antibody 
(aHCAR2) for 1 h and activated with LPS, in the presence 
or absence of MMF for 30 min. The concentration of intra-
cellular NAD+/NADH was determined in the lysed cells 
by a colorimetric reaction using NAD+/NADH Cell-Based 
Assay Kit (Cayman Chemical).
EAE induction and DMF treatment
Female C57BL/6J mice, 6–8 weeks old, weighing 
18.5 ± 1.5 g, were purchased from Harlan Italy. All ani-
mals were housed in pathogen-free conditions and treated 
according to the Italian and European guidelines (Decreto 
Legislativo 4 marzo 2014, n. 26, legislative transposition of 
Directive 2010/63/EU of the European Parliament and of 
the Council of 22 September 2010 on the protection of ani-
mals used for scientific purposes), with food and water ad 
libitum. The research protocol was approved by the Ethi-
cal Committees for Animal Experimentation of the Univer-
sity of Genoa and Tor Vergata University of Rome. After 
a 1-week period of adaptation to the animal house, mice 
were immunized as described before [59] by subcutane-
ous injection at two sites in the flank with an emulsion of 
200 μg myelin oligodendrocyte glycoprotein (MOG) pep-
tide 35–55 (Espikem) in incomplete Freund adjuvant (IFA; 
Difco) containing 300 μg Mycobacterium tuberculosis 
(strain H37Ra; Difco). Mice were injected in the tail vein 
with 400 ng pertussis toxin (Sigma-Aldrich) immediately 
and 48 h after immunization. The mice were scored daily 
for clinical manifestations of EAE on a scale of 0–5 [59].
The DMF suspension (15 mg/ml) in 0.8 % hydroxypro-
pyl methylcellulose was prepared weekly and kept at 4 °C 
under constant stirring. DMF (200 μl corresponding to a 
dose of 150 mg/kg body weight) was administered daily 
by oral gavage through a bulb-tipped curved gastric gav-
age needle by trained operators from the onset of clinical 
symptoms until day 30. Control EAE animals were gav-
aged with vehicle alone. Mice were treated and daily 
assessed in a random order. For sampling and at comple-
tion of the experiment, mice were euthanized by gradual-
fill CO2 exposure.
Electrophysiological studies
Electrophysiological experiments were performed as pre-
viously described [9, 40, 41]. Briefly, mice were killed 
by cervical dislocation under halothane anesthesia, and 
vibratome-sectioned corticostriatal coronal slices (200 μm) 
were prepared from fresh tissue blocks of the brain [9, 
40, 41]. A single slice was then transferred to a record-
ing chamber and submerged in a continuously flowing 
artificial CSF (ACSF) (34 °C, 2–3 ml/min) gassed with 
95 % O2–5 % CO2. Whole-cell patch clamp recordings 
were made in voltage clamp mode, at the holding poten-
tial of −80 mV to study spontaneous glutamate-mediated 
excitatory post-synaptic currents (sEPSCs). Bicuculline 
(10 µM) (Sigma-Aldrich) was added to the bathing ACSF 
to block GABAA-mediated transmission. Synaptic events 
were stored using P-CLAMP 9 (Axon Instruments) and 
analyzed offline on a personal computer with Mini Analy-
sis 5.1 (Synaptosoft) software. The detection threshold of 
sEPSCs was set at twice the baseline noise. Offline analy-
sis was performed on sEPSCs recorded during fixed time 
epochs (2–3 min, 3–6 samplings), sampled every 2 or 
5 min. Only cells that exhibited stable frequencies (less 
than 20 % changes during the control samplings) were 
taken into account. For kinetic analysis, events with peak 
amplitude between 10 and 50 pA were grouped, aligned by 
half-rise time, normalized by peak amplitude. For each cell, 
the events were averaged to obtain rise times, decay times, 
and half widths. The effects of microglia on striatal excita-
tory transmission were assessed as described [9] by plac-
ing N9 cells (2.5 × 105) onto the surface of a striatal slice, 
submerged in an oxygenated recording chamber for 30 min 
before electrophysiological recordings. One to six cells per 
mouse were recorded. For each group, at least four animals 
were assessed.
Statistical analysis
Results are presented as mean ± standard error of the mean 
(SEM). The difference in means between two groups was 
assessed by two-tailed Student t test. Statistical analysis 
was performed using Prism 5 (GraphPad Software). P val-
ues were considered significant at P < 0.05 and highly sig-
nificant at P < 0.01 and P < 0.001.
For the electrophysiological studies, statistical analy-
sis was performed using paired or unpaired Student t 
test if comparisons were between two groups. Multiple 
283Acta Neuropathol (2015) 130:279–295 
1 3
comparisons were analyzed by one-way ANOVA for inde-
pendent measures followed by Tukey’s honest significance 
test.
Results
Upon in vitro exposure to MMF, LPS‑activated 
microglia downregulate expression of inflammatory 
molecules and upregulate expression of alternative 
activation markers
As a pre-requisite to in vitro investigation of MMF effect on 
microglia, we evaluated the potential cytotoxicity of MMF, 
the bioactive metabolite of DMF, on N9 cells by measuring 
viability and proliferation upon 24-h exposure to increas-
ing concentrations of MMF. MTT assay results show that 
at the selected range (1–100 μM) MMF was not toxic for 
N9 cells (Supplementary Fig. S1a). To select the optimal 
effective concentration of MMF, we analyzed the mRNA 
expression by MMF-treated and untreated LPS-activated 
N9 cells of genes representative of classical (tumor necro-
sis factor α, Tnf; nitric oxide synthase inducible, Nos2) and 
alternative activation (chemokine (C-X3-C motif) receptor 
1, Cx3cr1; nuclear receptor related 1 protein, Nr4a2) phe-
notypes. We observed that, while Tnf and Nos2 were down-
regulated at all MMF concentrations tested, the lowest one, 
1 μM, was the most effective in reducing the expression 
of Cx3cr1 and Nr4a2 to basal levels (Supplementary Fig. 
S1b); the effect of MMF on microglia activation was there-
fore tested at this concentration in all subsequent in vitro 
studies.
The effect of MMF on expression of molecules asso-
ciated with a pro-inflammatory microglial phenotype is 
shown on Fig. 1a. Exposure to MMF led to a full rever-
sal to basal expression levels or strong downregulation of 
the genes coding for the inflammatory cytokines, Tnf and 
interleukin-1β (Il1b), the myeloid transcription factor, 
31 kDa-transforming protein/SFFV proviral integration 1 
protein (Spi1, also known as PU.1), which is critical for 
the viability and effector functions of microglia, and the 
stress response molecules heme oxygenase-1 (Hmox1) and 
Nos2, all of which were strongly upregulated by N9 cells 
upon LPS activation (Fig. 1a). In parallel, the expression 
of chemokine (C-X3-C motif) receptor 1 (Cx3cr1) and 
CD200 receptor (Cd200r), receptors essential for the main-
tenance of interactions with ligands expressed by neurons 
and whose disruption results in highly activated neurotoxic 
microglia [8, 61], as well as of that of Nr4a2, an orphan 
nuclear receptor which functions to inhibit expression of 
pro-inflammatory neurotoxic mediators in both microglia 
and astrocytes [42], was reversed or increased over basal 
levels upon exposure of LPS-activated microglia to MMF 
(Fig. 1b). We subsequently analyzed the effect of MMF on 
microglial expression of other genes coding for markers 
associated with an alternative activation phenotype, insu-
lin growth factor 1 (Igf1) [52], arginase 1 (Arg1) [62], and 
resistin-like alpha found in inflammatory zone (Retnla, also 
known as Fizz1) [35], and confirmed the effect of MMF in 
modulating the classically activated LPS-induced micro-
glial phenotype to that of an alternatively activated pheno-
type, with reversion to basal levels and/or high enhance-
ment of the expression of these factors (Fig. 1b).
These molecular data therefore strongly support our 
hypothesis that MMF acts on activated microglia by induc-
ing a switch from a classically activated, pro-inflammatory 
to an alternatively activated, potentially neuroprotective 
phenotype.
MMF induces functional modifications commensurate 
with an alternative activation phenotype 
in LPS‑activated microglia in vitro
To evaluate if the molecular changes observed in activated 
microglia upon exposure to MMF correlates with relevant 
functional modifications, we analyzed phagocytic func-
tion and intracellular Ca2+ concentration ([Ca2+]i), which 
are linked to executive microglia function such as release 
of pro- and anti-inflammatory cytokines, nitric oxide or 
trophic factors [7]. In LPS-activated N9 cells, exposure to 
MMF further enhanced the phagocytosis in vitro of fluo-
rescent microbeads (Fig. 2a, b). Most importantly, this 
increased phagocytic activity was associated with an 
increase in the expression of triggering receptor expressed 
by myeloid cells-2 (Trem2) mRNA, which codes for a mol-
ecule involved in the clearance of apoptotic neurons and 
myelin debris by microglia in the absence of inflammation 
[21, 50], and which was downregulated upon microglial 
activation (Fig. 2c).
Fluorometric determination of [Ca2+]i in N9 cells incu-
bated with the fluorescent calcium indicator Fura 2 AM 
demonstrated an increased [Ca2+]i upon activation with 
LPS, and this increase was further enhanced when the acti-
vated cells were treated with MMF (Fig. 2d).
These data indicate that the molecular phenotypic 
changes induced by MMF are accompanied by functional 
changes that are consistent with the phenotype of microglia 
involved in the maintenance of CNS homeostasis such as 
phagocytosis in the absence of inflammatory responses.
The anti‑inflammatory action of MMF is mediated 
through signaling via HCAR2
While the mechanisms of action of DMF and of its metabo-
lite MMF are only partially understood, MMF was recently 
shown to be a potent agonist of the hydroxycarboxylic 
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acid receptor, HCAR2 [20, 51]. We therefore hypothesized 
that the activity of MMF on microglia may involve bind-
ing to, and activation of, this receptor. While HCAR2 was 
shown to be expressed by a large number of cells, including 
immune cells [12, 20, 29, 58], its expression in microglia 
has not been directly demonstrated at the protein level. We 
therefore ascertained its expression in murine microglia-
derived N9 cells by confocal microscopy analysis upon 
co-staining with anti-HCAR2 (aHCAR2) and anti-CD11b 
antibodies. As can be seen in Fig. 3a, HCAR2 is expressed 
by N9 cells.
To determine if the modulating effect of MMF on micro-
glia is mediated through binding to HCAR2, we blocked 
the MMF/HCAR2 interaction using aHCAR2, as specific 
antagonists for HCAR2 are not available, and tested the 
expression of genes coding for molecules associated with 
the classical activation phenotype, Tnf, Il1b, and Hmox1, 
as well as molecules associated with the alternative acti-
vation phenotype, Nr4a2, Cx3cr1, and Cd200r. Antibody 
blockade of HCAR2 fully reversed the effect of MMF 
on the mRNA expression of inflammatory and oxida-
tive response molecules, Tnf, Il1b, and Hmox1, as well as 
that of Nr4a2 in activated microglia (Fig. 3b). In contrast, 
exposure to aHCAR2 had no effect on the upregulation of 
Cx3cr1 and Cd200r expression in MMF-treated activated 
microglia (Fig. 3b).
Fig. 1  MMF induces a molecular switch in activated microglia from 
a pro-inflammatory to an alternatively activated phenotype. Real-
time PCR analysis of mRNA expression of relevant genes in LPS-
activated N9 cells treated with MMF shows that a MMF decreases 
the expression of genes associated with a pro-inflammatory pheno-
type in activated microglia; and b MMF upregulates the expression 
of neuroprotective (alternatively activated) phenotype markers in 
activated microglia. Data are presented as fold induction over the 
expression of the genes in untreated N9 cells, and results are shown 
as mean ± SEM of at least three independent experiments. *P < 0.05 
and **P < 0.01
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We noted that the expression of many of the tested genes 
modulated by MMF exposure were dependent on NF-κB 
activation, including Tnf, Il1b, Sp1, Hmox1, Nos2, and 
Nr4a2 [6, 25, 26, 31, 33, 37, 44, 60]. Of these gene tran-
scripts, four that were also tested for their expression in 
LPS-activated MMF-treated microglia upon blockade of 
HCAR2, Tnf, Il1b, Hmox1, and Nr4a2 showed reversed 
expression levels under this condition, whereas the expres-
sion of non-NF-κB-dependent Cx3cr1 and Cd200r was 
unaltered (Fig. 3b); suggesting that the NF-κB pathway is 
implicated in the modulation of the inflammatory pheno-
type of microglia by MMF activation of HCAR2 signaling.
MMF modulates microglia activation phenotype 
through inhibition of the NF‑κB pathway via the 
AMPK/Sirt1 axis
Based on the above demonstration that MMF induced 
an increase in [Ca2+]i and resulted in the inhibition of 
NF-κB-dependent gene expression, together with previ-
ous studies showing that activation of HCAR2 resulted in 
increases in [Ca2+]i [3, 20], we hypothesized that MMF 
was initiating an HCAR2-dependent downstream signaling 
pathway activated by the increase in intracellular Ca2+ lev-
els (Fig. 4). Thus, activation of HCAR2 upon MMF bind-
ing would lead to activation of the Gi-type G protein sign-
aling cascade; this, in turn, would result in phospholipase 
C activation, possibly through release of the βγ subunit [4] 
and, thereby, in increased [Ca2+]i. The increase in [Ca
2+]i 
would lead to activation of AMPK through phosphorylation 
of threonine 172 by calcium/calmodulin-dependent protein 
kinase 2 (CaMKK2) [22] whose activity is enhanced by 
[Ca2+]i [1]. It has been shown that the NAD+-dependent 
protein deacetylase sirtuin-1 (SIRT 1) suppresses NF-κB 
by direct deacetylation at lysine 310 of NF-κB p65 [57]. 
As its deacetylase activity is regulated by NAD+ availabil-
ity [38]; we postulated that AMPK activation would lead to 
an increase in NAD+ generated through phospho-AMPK 
(p-AMPK)-mediated induction of nicotinamide phosphori-
bosyltransferase (NAMPT), the rate-limiting enzyme in the 
NAD biosynthesis pathway [14], and thereby in activation 
of SIRT1 resulting in inhibition of NF-κB signaling [23, 
32].
As the first step towards validating this possible path-
way, we demonstrated that the increased [Ca2+]i is indeed a 
result of MMF binding to HCAR2, as blocking the receptor 
Fig. 2  MMF prompts func-
tional changes associated 
with an alternatively activated 
phenotype of microglia. MMF 
enhances the phagocytic activ-
ity of LPS-activated N9 cells 
in vitro as shown by confocal 
microscopy images of LPS-
activated N9 cells treated or not 
with MMF in the presence of 
green fluorescent microspheres 
(a) and quantified as the cell 
area occupied by the micro-
spheres (b); the average cell 
section area was 34 ± 1 and 
180 ± 7 μm2 for non-activated 
and activated cells, respec-
tively. c MMF upregulates 
mRNA expression of Trem2 in 
LPS-activated N9 cells. Data 
are presented as fold induction 
over the expression of Trem2 
in untreated N9 cells. d MMF 
increases [Ca2+]i in LPS-
activated N9 cells, as measured 
by fluorometric analysis of 
Fura 2AM. Results are shown 
as mean ± SEM of at least 
three independent experiments. 
*P < 0.05 and ***P < 0.001. 
Bar = 15 μm
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with aHCAR2 prevented the MMF-induced [Ca2+]i flux 
observed in Fura 2AM-treated LPS-activated N9 cells upon 
exposure to MMF (Fig. 5a).
We then quantified p-AMPK by Western blotting to 
assess AMPK activation as the first downstream component 
of the pathway and observed a decrease in the proportion 
of p-AMPK in LPS-activated N9 cells. In the presence of 
MMF, however, there was a clear increase in p-AMPK, 
and this increase was inhibited upon blocking HCAR2 
(Fig. 5b).
The ensuing step of this pathway implicates an activa-
tion of NAMPT that converts NAM to NAD+, essen-
tial for the activation of SIRT1, and we measured NAD+ 
concentration in LPS-activated N9 cells exposed, or not, to 
MMF and upon antibody blockade of HCAR2. As can be 
seen in Fig. 5c, the expected increase in NAD+ upon expo-
sure to MMF and its reversal in the presence of aHCAR2 
support an activation of NAMPT in the HCAR2 pathway 
triggered by MMF.
To validate the last step of the pathway, which impli-
cates the activation of the NAD+-dependent SIRT1 lead-
ing to deacetylation of NF-κB and therefore its inhibition, 
we measured the outcome of the enzymatic reaction, that is 
we monitored the acetylation status of NF-κB in N9 cells, 
upon various treatments aimed at assessing the effect not 
only of blocking MMF binding to HCAR2 with aHCAR2, 
Fig. 3  MMF signals through binding to HCAR2. a N9 cells express 
HCAR2. Confocal microscopy images of N9 cells stained with 
anti-HCAR2 (green) and anti-CD11b (red) antibodies, and with the 
nuclear marker DAPI (blue). Bars = 20 and 5 μm for left and right 
panels, respectively. Magnification = 40× and 100× for left and 
right panels, respectively. b Blocking HCAR2 reverts the effect of 
MMF on the expression of genes dependent on NF-κB, but not on 
that of Cx3cr1 and Cd200r. N9 cells were incubated with or without 
anti-HCAR2 antibody (aHCAR2) for 1 h prior to LPS activation for 
6 h in the presence or absence of MMF, and mRNA expression of the 
indicated genes was assessed by real-time PCR. Data are presented as 
fold induction over the expression of the genes in untreated N9 cells 
and results are shown as mean ± SEM of at least three independent 
experiments. *P < 0.05, **P < 0.01
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but also of inhibiting SIRT1 itself with the SIRT1-specific 
inhibitor, EX527, or activating it directly with a specific 
activator, Resveratrol (Resv) (Fig. 5d). Densitometric 
quantification of Western blots demonstrated that the 
increase in Ac-NF-κB upon LPS activation was reversed 
by MMF and that this effect was abrogated in presence of 
aHCAR2, suggesting that SIRT1 activation is implicated 
in MMF effect via HCAR2 signaling. Along those lines, 
exposure of LPS-activated MMF-treated N9 cells to an 
inhibitor of SIRT1, EX527, had a similar effect as HCAR2 
blockade (Fig. 5d). As a control to our study and to sup-
port the implication of SIRT1 in the effect of MMF, we 
exposed LPS-activated N9 cells to Resv and observed a 
reduction in Ac-NF-κB similar to that seen upon exposure 
to MMF (Fig. 5d).
Altogether, these data support the model in which the 
anti-inflammatory effects of MMF on microglia are medi-
ated through activation of the AMPK/SIRT1 axis, resulting 
in inhibition of NF-κB, which controls the expression of 
multiple inflammatory cytokines and mediators.
DMF treatment leads to an increased expression 
of markers of alternatively activated microglia in CNS 
of EAE mice
To ascertain whether or not the effects of MMF that we had 
observed in vitro are recapitulated in vivo, we tested the 
therapeutic effect of its precursor, DMF, in C57Bl/6J mice 
with chronic EAE induced with MOG peptide. Mice were 
treated by daily oral gavage with 150 mg/kg body weight 
DMF suspended in hydroxypropyl methylcellulose  (mean 
MMF plasma concentration ± SEM: 49.81 ± 9.57 μg/ml 
at 30 min after dosing; data not shown) from the day fol-
lowing the onset of clinical symptoms until day 30 after 
immunization when the chronic disease phase is well estab-
lished. As seen in Fig. 6a, we confirmed the reported ben-
eficial effect of DMF on MOG-induced EAE [28]. Thus, a 
significantly lower clinical severity was observed in EAE-
affected mice treated with DMF from day 16, that is 4 days 
after the start of treatment, which remained significant 
until day 22, i.e., throughout the peak/early chronic phase 
(Fig. 6a, left panel); statistical analysis of the area under 
the curve (AUC) from days 15 to 30 post-immunization 
showed significant difference between DMF-treated and 
untreated mice (Fig. 6a, right panel; P < 0.05).
To determine the effect of DMF on the brain environ-
ment in EAE mice, we analyzed the mRNA expression of 
markers for inflammatory molecules, Tnf, Il1b, and Nos2, 
as well as for markers of alternative activation, Arg1, 
Retnla, mannose receptor C type 1 (Mrc1; also known as 
Cd206) and lectin galactose binding, soluble 3 (Lgals3; also 
known as Gal3) in brain from three DMF-treated (DMF) 
mice and three untreated (Vehicle) mice (Fig. 6b), at rel-
evant time points corresponding to acute (day 15), post-
peak/early chronic (day 22), and chronic (day 30) phases. 
While there was no significant difference in brain Tnf 
expression between treated and untreated mice at any time 
point tested, the expression of Il1b was significantly down-
regulated in DMF-treated mice at day 15; similarly, albeit 
not significant, there was a trend towards lower expression 
of Nos2 at the same time point. Markers of alternatively 
activated phenotype were significantly increased in brain of 
DMF-treated EAE-affected mice in the early phase of dis-
ease (Fig. 6b). By day 30, at the established chronic phase 
when a significant difference in disease severity was no 
longer detected between DMF-treated and untreated mice, 
the expression levels of all these markers in DMF-treated 
mice had returned to those of untreated mice (Fig. 6b).
These results confirm that oral administration of DMF 
to mice with EAE results in clinical amelioration and 
can induce an increase in the expression of markers of an 
Fig. 4  Postulated signaling pathway for MMF through binding to 
HCAR2
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alternatively activated phenotype, as observed in microglia 
exposed in vitro to MMF.
Validation of DMF effect at the synaptic level: DMF 
protects glutamatergic synapses
In EAE, neuroinflammation enhances glutamate transmis-
sion and promotes synaptopathy, which occurs in the early 
phase of disease and is associated with the release of inflam-
matory cytokines, such as TNFα and IL-1β, from activated 
microglia [9, 30]. To understand whether or not DMF 
might affect EAE-mediated synaptopathy, we have per-
formed whole-cell patch clamp electrophysiological record-
ings from single neurons in corticostriatal slices from EAE 
mice, treated or not with DMF, and control mice, between 
20 and 25 days post-immunization (post-peak/early chronic 
phase of disease). As in our previous studies [9, 40, 41], we 
observed pre- and post-synaptic abnormalities of glutamater-
gic transmission in EAE mice (Fig. 7). Thus, both frequency 
and kinetic properties of glutamate-mediated sEPSCs were 
altered in EAE mice, as compared to that in control mice, 
with a longer decay time accounting for increased sEPSC 
duration. DMF treatment normalized sEPSC frequencies 
(P < 0.05 as compared to vehicle-gavaged EAE-affected 
mice; Fig. 7a), but had no effect on the increase in sEPSC 
decay time and half-width (Fig. 7b, c, f). Neither rise time 
nor amplitude of sEPSCs was altered by EAE induction, as 
previously shown [9], or by DMF treatment (Fig. 7d, e).
Fig. 5  Validation of the HCAR2-mediated pathway for MMF sign-
aling. a Blocking HCAR2 suppresses MMF-induced increase in 
[Ca2+]i in activated microglia. N9 cells were incubated with or with-
out aHCAR2 for 1 h prior to LPS activation for 6 h in the presence or 
absence of MMF and [Ca2+]i was determined by fluorimetric analy-
sis. b MMF treatment activates AMPK in LPS-activated microglia. 
Representative Western blot (left panel) and quantification (right 
panel) of at least three Western blot analyses of N9 cell lysates are 
shown. N9 cells were incubated or not with aHCAR2 prior to activa-
tion with LPS for 30 min in the presence or absence of MMF. West-
ern blot analysis of the lysates was performed with anti-p-AMPK, 
which recognizes phosphorylated Thr172, anti-AMPK, and anti-
GRB2 (as loading control) antibodies. Quantification by densito-
metric analysis of Western blot films is presented as the proportion 
of p-AMPK over total AMPK (fold induction over N9), normalized 
to GRB2. Results are shown as mean ± SEM of at least three inde-
pendent experiments; *P < 0.05. c MMF treatment increases NAD+ 
levels in LPS-activated microglia. Graph represents colorimetric 
quantification of intracellular NAD+ produced by N9 cells incubated 
with or without aHCAR2 prior to activation with LPS in the presence 
or absence of MMF for 30 min. d MMF treatment leads to NF-κB 
inhibition in activated microglia through deacetylation of NF-κB 
p65. Representative Western blot (left panel) and quantification (right 
panel) of at least three Western blot analyses of N9 cell lysates are 
shown. N9 cells were incubated with or without aHCAR2 and/or 
EX527 (10 μM) for 1 h prior to activation with LPS in the presence 
or absence of MMF or Resv (50 μM) for 6 h. Western blot analy-
sis was performed with anti-Ac-NF-κB antibody, which recognizes 
acetylated lysine 310 of NF-κB p65, anti-NF-κB, and anti-GRB2 (as 
loading control) antibodies. Quantification by densitometric analy-
sis of Western blot films is presented as the proportion of Ac-NF-κB 
over total NF-κB (fold induction over N9). Results are shown as 
mean ± SEM of at least three independent experiments; *P < 0.05
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These data might indicate that DMF directly alters sEP-
SCs in EAE mice by modulating basal glutamatergic trans-
mission at central synapses. Thus, we tested the effect of 
MMF, the active metabolite of DMF, on spontaneous syn-
aptic transmission. Upon exposure of corticostriatal slices 
from control mice to MMF, we observed a direct effect 
on neuronal synaptic activity. Thus, MMF at the low con-
centration (1 μM) significantly reduced sEPSC frequency 
(P < 0.01), but not amplitude (100.8 ± 1.6 vs. 100 % pre-
treatment values; data not shown) in all the tested control 
Fig. 6  Treatment with DMF ameliorates EAE and induces an 
increase in markers of alternatively activated microglia in vivo. 
a Administration of DMF at clinical onset reduces EAE sever-
ity at post-peak/early chronic phase. C57BL/6J mice (n = 20 per 
group, randomly allocated) were immunized with MOG 35–55 and 
treated daily by oral gavage with DMF (DMF) or with hydroxy-
propyl methylcellulose  alone (Vehicle) from the day of disease 
onset until day 30 post-immunization. Mice (n = 3 per group at 
each time point) were sampled at indicated time points (arrows) for 
PCR analysis of brain mRNA (see below). Data are presented as the 
mean ± SEM daily clinical score (left panel) and as the area under 
the curve (AUC) of EAE clinical course calculated for each mouse 
between days 15–30 post-immunization (right panel). *P < 0.05, 
#P < 0.01. b In vivo treatment with DMF downregulates the expres-
sion of pro-inflammatory genes and upregulates genes of the alterna-
tively activated microglia phenotype in the CNS of EAE mice. RNA 
was isolated from brains of EAE mice treated or not with DMF at 
indicated time points corresponding to acute (day 15), post-peak (day 
22) and chronic (day 30) phases. Expression of the indicated genes 
was quantified by real-time PCR. Results are shown as mean ± SEM. 
*P < 0.05, **P < 0.01
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neurons (Fig. 7g), indicating that MMF directly modulates 
glutamatergic transmission at the pre-synaptic level.
Alternatively, DMF might also alter sEPSCs in EAE 
mice by an indirect immunomodulatory mechanism 
through its effect on microglia. As the exposure of striatal 
slices from control mice to activated microglia results in 
altered glutamate transmission such as seen in EAE, an 
effect that can be attributed to TNFα released from the acti-
vated microglia [9], we directly tested the effects of MMF 
on microglia action at synapses. While non-activated N9 
cells had no effect on the physiological properties of striatal 
sEPSCs recorded from control slices (Fig. 8a–c), exposure 
of control slices to LPS-activated N9 cells significantly 
increased the duration of sEPSCs (P < 0.001; Fig. 8b, d), 
by slowing their decay phases (P < 0.001; Fig. 8c, d). We 
hypothesized that the lack of protective effects of DMF 
on sEPSC duration in EAE mice could be related to a low 
central exposure of MMF after oral gavage (dose-limiting 
toxicity prevents testing higher chronic doses). Indeed, 
treatment of activated microglia with a high concentration 
Fig. 7  DMF treatment normalizes pre-synaptic abnormalities of glu-
tamatergic transmission in EAE mice. a–e DMF treatment normalizes 
the frequency, but not the increased decay time and half-width of glu-
tamatergic sEPSCs of EAE mice. sEPSC recordings from single stri-
atal neurons (n = 12 neurons for a total of four mice for each group) 
were performed on EAE mice sampled between day 20 and day 25 
post-immunization. Corticostriatal slices obtained from naïve mouse 
brain (Control) were used for control recordings (n = 14 neurons 
recorded for a total of four mice). *P < 0.05. f Representative elec-
trophysiological traces of voltage clamp recordings. g MMF applied 
directly on control corticostriatal slices induces significant reduction 
of sEPSC frequency. MMF (1 μM) was added to the bathing ACSF 
from the indicated time and continuously for 12 min. Recordings 
were performed on single striatal neurons (n = 10)
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of MMF (100 μM) fully prevented the increase of sEPSC 
duration, whereas their treatment with a low concentration 
(1 μM) had no such effect (Fig. 8b–d).
These findings support the concept that the neuroprotec-
tive effect of DMF is exerted on neurons directly at pre-
synaptic terminals by modulating glutamate release, and 
indirectly at post-synaptic level, by modulating microglia 
function in a dose-dependent manner.
Discussion
In this study, we show that the therapeutic effect of DMF, 
which leads to neuroprotection in EAE, could be medi-
ated at the level of the CNS not only by directly affecting 
neurons through induction of the Nrf2-mediated anti-oxi-
dative pathway [28], but also through direct modulation 
of the activation state of microglia, inducing reversal, or a 
strong downregulation, of activation-induced expression of 
inflammatory and stress response genes and upregulation of 
genes associated with an alternatively activated and there-
fore neuroprotective phenotype of microglia. Moreover, we 
postulate and validate an Nrf2-independent pathway trig-
gered by MMF binding to HCAR2 through which DMF 
can act to switch microglia phenotype from pro- to anti-
inflammatory, thereby indirectly affecting neuronal survival 
and function.
The anti-inflammatory action of DMF/MMF on micro-
glial cells is known, with in vitro studies on LPS-activated 
mixed glial cells, astrocytes and microglia, showing rever-
sal of the LPS-induced release of inflammatory cytokines 
[54, 55], but it has been generally attributed to the anti-
oxidative action of DMF through activation of the Nrf2 
pathway, as occurs in neurons [28]. However, studies have 
shown that DMF also inhibits NF-κB [27, 47], one of the 
most potent activating transcription factors of pro-inflam-
matory genes. While Nrf2 can modulate NF-κB activity 
within a regulatory feedback loop [11], the evidence for the 
possible implication of Nrf2 activation in MMF effect on 
microglia is scant and poor [28, 54, 55]. We hypothesized 
that Nrf2-independent pathways, which were recently dem-
onstrated in Nrf2−/− mice [46], might also be implicated in 
immune modulation by DMF. We therefore examined the 
possibility that a pathway resulting in inhibition of NF-κB, 
and thereby of relevant inflammatory molecules, could be 
triggered by MMF binding to HCAR2. Indeed, HCAR2 is 
implicated in the flushing reaction to DMF [20], and MMF 
has been identified as a potent HCAR2 agonist [51]. Our 
Fig. 8  DMF modulates microglia action at synapses. (a–c) The 
increase in sEPSC decay time and half-width induced upon exposure 
of control corticostriatal slices to LPS-activated microglia is reverted 
when activated microglia are treated with MMF at high concentra-
tion. Corticostriatal slices obtained from naïve mouse brain were 
exposed to microglia activated with LPS in the presence or absence 
of 1 or 100 μM MMF (N9 + LPS + MMF 1 μM or 100 μM) for 
30 min prior to electrophysiological recordings from single striatal 
neurons (n = 11). Control recordings were obtained from untreated 
slices (Untreated) or slices exposed to N9 cells (N9) or N9 cells acti-
vated with LPS (N9 + LPS); ***P < 0.001. d Electrophysiological 
traces are example of mean peak obtained by group analysis in the 
presence of activated microglia untreated or treated with high-dose 
MMF
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immunohistochemical demonstration of the presence of 
HCAR2 on microglia corroborated the recent report that in 
the ischemic mouse brain, HCAR2 is expressed exclusively 
by CD11b+ microglia but not by astrocytes or neurons 
[36]. We used the anti-HCAR2 antibody to block our pos-
tulated pathway whereby activation of HCAR2 by MMF 
leads to deacetylation, and thereby inhibition, of NF-κB via 
the AMPK/SIRT1 axis triggered by the increase in intracel-
lular calcium known as a consequence of HCAR2 signaling 
[51]. At each relevant step analyzed, blockade of HCAR2 
reversed the effect of MMF on the relevant pathway com-
ponent, demonstrating that MMF does signal through 
HCAR2 to modulate the expression of molecules depend-
ent upon NF-κB activation. In this context, it is relevant to 
note that the expression of Hmox1, which is upregulated 
upon activation of Nrf2 [24] but whose expression is also 
dependent upon NF-κB [25], was downregulated upon 
triggering of the HCAR2 pathway by MMF in microglia. 
The possibility that MMF can modulate microglia activa-
tion through binding to HCAR2 is of utmost relevance in 
the context of accumulating evidence implicating HCAR2 
signaling in the regulation of immune cell function and 
inflammation in general. HCAR2 is expressed in various 
immune cells [5] and studies with the HCAR2 ligand, nico-
tinic acid, have demonstrated the anti-inflammatory effect 
of HCAR2 activation. In particular, Zandi-Nejad et al. [58] 
showed that activated macrophages are subject to negative 
feedback mechanism via HCAR2 signaling, with suppres-
sion of LPS-induced pro-inflammatory cytokine production 
upon exposure to nicotinic acid, an effect that correlated 
with NF-κB inactivation. Interestingly in the context of our 
present study, HCAR2 activation in bone marrow-derived 
inflammatory macrophages that infiltrate the brain in a 
mouse model of stroke induces a neuroprotective pheno-
type in these cells [36]. Similar anti-inflammatory effects 
associated with activation of HCAR2 in macrophages were 
demonstrated in a model of atherosclerosis in chimeric 
mice reconstituted with wild-type vs. HCAR2-deficient 
bone marrow, where the strong lipid-independent inhibitory 
effect of nicotinic acid on the progression of atherosclero-
sis was shown to be mediated by its receptor HCAR2 on 
bone marrow-derived cells [29]. It is interesting to note in 
this context that activation of the AMPK/SIRT1 axis antag-
onizes fatty acid-induced inflammation in macrophages 
[56]. Importantly, recent studies have also suggested a 
potential anti-inflammatory role for the endogenous ligand 
for HCAR2, butyrate [5, 49]. Thus, it is noteworthy that 
butyrate induces the differentiation of regulatory T cells 
in vitro and in vivo [2, 15], and ameliorated the develop-
ment of colitis induced by adoptive transfer of CD4(+) 
CD45RB(hi) T cells in Rag1(−/−) mice [15]. A recent 
study showed that butyrate, produced in the colon by gut 
microbiota, induced the expression of anti-inflammatory 
molecules in colonic macrophages and dendritic cells in 
an HCAR2-dependent manner enabling them to promote 
the differentiation of naïve T cells into regulatory T cells 
and protecting them against colitis [48]. Our data there-
fore reinforce the importance of the HCAR2 pathway in 
inflammation and also suggest its potential relevance for 
neuroinflammation mediated by microglia. Our data also 
suggest that administration of DMF, which, after hydroly-
sis to MMF, crosses the blood–brain barrier, is capable of 
dampening such neuroinflammation, thereby adding to the 
neuroprotective action recently proposed for DMF [28]. As 
we were completing the ex vivo experiments of this study, 
Chen et al. [10] published their report on EAE in Hcar2−/− 
mice which confirms a role for HCAR2 signaling in the 
effect of DMF. Using a preventive treatment paradigm, they 
observed that, while DMF administration in wild-type mice 
strongly downregulated disease expression as expected, it 
had no effect on EAE induced in Hcar2−/− mice, either at 
the clinical or neuropathological level. Through adhesion 
and migration assays of purified neutrophils from wild-type 
and Hcar2−/− mice, they attributed the protective effect of 
DMF in EAE to inhibition of neutrophil adhesion to brain 
endothelial cells, and thereby their extravasation into brain 
tissue, through activation of HCAR2, as reported for other 
Gi-coupled receptors [10]. While Chen et al. observed 
HCAR2 expression on macrophages/microglia, they did 
not address the possibility that DMF might modulate 
microglia activation through HCAR2 activation.
We confirm the data of Linker et al. [28] that therapeu-
tic administration of MMF in ongoing disease alleviates 
EAE. Our data further show that such amelioration is asso-
ciated with the promotion of a less inflammatory environ-
ment in the CNS of treated mice and with the upregulation 
of microglia markers typical of an alternatively activated 
homeostatic phenotype, an observation commensurate 
with previous demonstration that DMF treatment of mice 
induced to develop EAE results in reduced macrophage/
microglia infiltration/migration at early disease phase [28, 
45].
In the brain parenchyma, microglia interact intimately 
with neurons, contacting synaptic elements, and evidence 
is accumulating for a role of microglia in monitoring and 
eliminating synapses, thereby contributing to neuronal 
circuitry [7]. Thus, upon transient cerebral ischemia, the 
duration of microglia–synapse contacts was markedly pro-
longed and frequently followed by the disappearance of 
the pre-synaptic bouton [53]. We have shown that inflam-
mation in EAE triggers alteration of pre- and post-synaptic 
sites of glutamate synapses, an effect that could be attrib-
uted to activated microglia, as the effect of exposure of 
striatal slices from control mice to microglia activated by 
pro-inflammatory cytokines mimicked the alterations of 
glutamate transmission seen in EAE [9]. We have analyzed 
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the possibility that the modulating effect of DMF on micro-
glia activation could be reflected on synapse alterations 
both in vivo and in vitro. Through whole-cell patch clamp 
electrophysiological recordings from single neurons in cor-
ticostriatal slices, we confirmed the increase in excitatory 
transmission in ongoing EAE and showed that, while DMF 
treatment did not affect the half-width and decay time of 
sEPSCs of striatal neurons in DMF-treated EAE mouse 
brain, their frequency was reverted to that in control mouse 
brain, indicating that administration of DMF by oral gav-
age normalizes pre-synaptic alterations in ongoing EAE, 
an effect that was corroborated in vitro through exposure 
of control corticostriatal slices to MMF. That DMF mod-
ulates microglial activation in such a way as to revert the 
neurotoxic effect of activated microglia to a neuroprotec-
tive one is reflected by our data showing that, while expo-
sure of control corticostriatal slices to LPS-activated micro-
glia led to an increase in sEPSC half-width and decay time, 
representative of altered glutamatergic transmission such 
as seen in EAE and reported previously [9], treatment of 
the activated microglia with MMF reverted such an effect. 
These data therefore indicate that MMF can act at post-syn-
aptic level to normalize glutamate transmission indirectly 
through its modulating effect on microglia.
Altogether, the data reported here demonstrate a possi-
ble mode of action for DMF in inflammatory neurodegen-
erative diseases through its direct effect on inflammatory 
microglia, which is potentiated by its capacity to cross the 
blood–brain barrier as shown by pharmacological evidence 
of the presence of MMF in murine brain upon oral gavage 
at concentrations commensurate with those shown to affect 
microglia activation in the present study. Most importantly, 
our data demonstrate HCAR2 signaling, which has been 
increasingly implicated in inflammatory processes, as the 
relevant AMPK/SIRT1-mediated pathway for the effect of 
MMF on inflammatory microglia, suggesting that HCAR2 
signaling is not only relevant to regulate immune cells at 
the periphery, but also in the CNS.
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